(Q38068231)

28 August 2017

1 reference

title

Re-emergence of pertussis: what are the solutions? (English)

1 reference

28 August 2017

2

Kathryn M Edwards

1 reference

28 August 2017

Romina Libster

1

1 reference

28 August 2017

publication date

1 November 2012

1 reference

Expert Review of Vaccines

28 August 2017

published in

1 reference

28 August 2017

volume

11

1 reference

28 August 2017

issue

11

1 reference

28 August 2017

page(s)

1331-1346

1 reference

Evidence of Bordetella pertussis infection in adults presenting with persistent cough in a french area with very high whole-cell vaccine coverage

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.118

Increased population prevalence of low pertussis toxin antibody levels in young children preceding a record pertussis epidemic in Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.118

Pertussis epidemiology in Argentina: trends over 2004-2007.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.118

Early Impact of the US Tdap vaccination program on pertussis trends.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.118

Reemergence of pertussis in the highly vaccinated population of the Netherlands: observations on surveillance data

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.118

California pertussis epidemic, 2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.118

The seroepidemiology of immunoglobulin G antibodies against pertussis toxin in China: a cross sectional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.118

Does this coughing adolescent or adult patient have pertussis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.118

Effectiveness of adolescent and adult tetanus, reduced-dose diphtheria, and acellular pertussis vaccine against pertussis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.118

Infant pertussis: who was the source?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.118

Accelerating control of pertussis in England and Wales

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.118

A "new age" in pertussis prevention new opportunities through adult vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.118

A search for Bordetella pertussis infection in university students

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.118

Efficacy of an acellular pertussis vaccine among adolescents and adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.118

The seroepidemiology of Bordetella pertussis in Israel--Estimate of incidence of infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.118

Infant and maternal risk factors for pertussis-related infant mortality in the United States, 1999 to 2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.118

Adverse events following pertussis and rubella vaccines. Summary of a report of the Institute of Medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.118

Efficacy of acellular pertussis vaccine in early childhood after household exposure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.118

Efficacy of a two-component acellular pertussis vaccine in infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.118

A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.118

Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.118

A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.118

A Controlled Trial of Two Acellular Vaccines and One Whole-Cell Vaccine against Pertussis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.118

A placebo-controlled trial of a pertussis-toxoid vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.118

Pertussis vaccination in infancy lowers the incidence of pertussis disease and the rate of hospitalisation after one and two doses: analyses of 10 years of pertussis surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.118

Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.118

Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.118

Unexpectedly limited durability of immunity following acellular pertussis vaccination in preadolescents in a North American outbreak

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.118

Adolescent and adult pertussis vaccination: computer simulations of five new strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.118

The impact of adolescent pertussis immunization, 2004-2009: lessons from Australia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.118

Adolescent vaccination-coverage levels in the United States: 2006-2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.118

Combined tetanus, diphtheria, and 5-component pertussis vaccine for use in adolescents and adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.118

Humoral immunity 10 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.118

Use of pertussis vaccine in an epidemic involving hospital staff

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.118

A pertussis outbreak in a Wisconsin nursing home.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.118

Pertussis vaccination in child care workers: room for improvement in coverage, policy and practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.118

Vaccination policies for health-care workers in acute health-care facilities in Europe.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.118

Knowledge, attitudes and vaccination coverage of healthcare workers regarding occupational vaccinations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.118

Transmission of Bordetella pertussis to young infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.118

Impact of postpartum information about pertussis booster to parents in a university maternity hospital.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.118

[Vaccination in parents of young infants survey]

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.118

Prospects for prevention of childhood infections by maternal immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.118

Tetanus toxoid and congenital abnormalities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.118

Poor immune responses to a birth dose of diphtheria, tetanus, and acellular pertussis vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.118

Th2-polarisation of cellular immune memory to neonatal pertussis vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.118

Epidemiology of pertussis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.118

Bordetella pertussis strains with increased toxin production associated with pertussis resurgence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.118

Newly emerging clones of Bordetella pertussis carrying prn2 and ptxP3 alleles implicated in Australian pertussis epidemic in 2008-2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.118

First report and detailed characterization of B. pertussis isolates not expressing Pertussis Toxin or Pertactin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.118

Changes in genetic diversity of the Bordetella pertussis population in the United Kingdom between 1920 and 2006 reflect vaccination coverage and emergence of a single dominant clonal type

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.118

Changes in the genomic content of circulating Bordetella pertussis strains isolated from the Netherlands, Sweden, Japan and Australia: adaptive evolution or drift?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.118

Population diversity among Bordetella pertussis isolates, United States, 1935-2009

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.118

New pertussis vaccination approaches: en route to protect newborns?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.118

Immunization with PCEP microparticles containing pertussis toxoid, CpG ODN and a synthetic innate defense regulator peptide induces protective immunity against pertussis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.118

Influence of maternal antibodies on active pertussis toxoid immunization of neonatal mice and piglets

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.118

Enhanced immune response against pertussis toxoid by IgA-loaded chitosan-dextran sulfate nanoparticles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.118

Effectiveness of two pertussis vaccines in preterm Danish children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.118

Identification of a new protective antigen of Bordetella pertussis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.118

Effect of different forms of adenylate cyclase toxin of Bordetella pertussis on protection afforded by an acellular pertussis vaccine in a murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.118

Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.118

Long-term immunity against pertussis induced by a single nasal administration of live attenuated B. pertussis BPZE1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.118

A live, attenuated Bordetella pertussis vaccine provides long-term protection against virulent challenge in a murine model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.118

Prospective Multinational Study of Pertussis Infection in Hospitalized Infants and Their Household Contacts

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.118

21 January 2018

Identifiers

DOI

10.1586/ERV.12.118

1 reference

28 August 2017

1 reference